SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Attention centers on TSMCs discussions about a potential role in Musks Texas Terafab project; traders debate whether its involvement would supplement Intels role or replace it, with no finalized deal established. The chatter also reflects bullish momentum and expectations that continued AI-chip demand will support TSMCs business.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Record quarterly results and a raised fiscal 2027 outlook, supported by AI data-center demand for Penguin Solutions infrastructure and memory businesses, are driving attention. Many traders are bullish on the beat-and-raise, while others debate whether the rally can hold amid profit-taking, resistance, and short-positioning concerns.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is under pressure as elevated long-term Treasury yields weigh on the fund, with traders pointing to inflation and oil risks, government debt and bond supply, and weakness in global bonds. Sentiment is broadly bearish, though some traders see oversold conditions and expect a rebound if yields ease.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist shares surged after Micron agreed to a five-year patent license and settlement that resolves the companies pending legal disputes. Traders largely view the recurring licensing revenue as a validation of Netlists memory patents, while debating whether the terms were favorable and speculating about a future SK hynix deal, Google developments, and a Nasdaq relisting.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Elon Musks discussions with TSMC about its potential role in the Terafab project have raised concerns that Intel could lose some of the foundry opportunity or its exclusivity, weighing on sentiment. Intels CEO says the company will remain involved, and traders are divided over whether TSMC would supplement Intel or compete for its role.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is drawing attention for persistent small-cap underperformance as mega-cap technology leads broader indexes, with traders citing elevated Treasury yields and small companies rate sensitivity as headwinds. The debate is whether support near the long-term trend can spark a catch-up bounce or whether weak breadth and high borrowing costs will prolong the decline.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Pharvaris positive Phase 3 results for an oral hereditary-angioedema prevention drug have intensified concerns that it could challenge BioCrysts Orladeyo and complicate the outlook for navenibart. Traders are debating whether the selloff overstates the threat, noting Pharvaris still needs to reach the market while BioCryst has an established product and patient base.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns post-earnings weakness and prolonged consolidation despite strong results dominate discussion. Traders debate profit-taking and cyclical-peak concerns against the view that AI-driven HBM and DRAM demand will remain strong; many are frustrated by the stocks underperformance, while others see the dip as temporary.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POETs business update citing production units in customer qualification, improving yields and plans to expand manufacturing has renewed interest in its commercialization progress. Bulls view it as evidence the ramp is advancing, while skeptics say the update lacks named customers and confirmed orders, prolonging concerns about execution and revenue timing.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIMs raised full-year earnings guidance is driving attention, with traders reacting positively while speculating that managements outlook is conservative and stronger results could support larger dividends. Discussion also weighs the earnings outlook against uncertainty over Israeli approval of the Hapag-Lloyd deal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?

Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst

Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.

Black Diamond Stock Outlook After Q1 Beat and Cash Runway

BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.

BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know

Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.

What's Going On With Black Diamond Therapeutics Stock Tuesday?

Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving averages, and price action.read more...

BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data

Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.

BDTX Shares Gain 11% in a Week: Here's What You Should Know

Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and continued progress for lead candidate silevertinib.

Black Diamond Therapeutics (BDTX) to Release Quarterly Earnings on Monday

Black Diamond Therapeutics (NASDAQ:BDTX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-black-diamond-therapeutics-inc-stock...

HC Wainwright Issues Positive Forecast for BDTX Earnings

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - HC Wainwright upped their Q1 2026 earnings estimates for shares of Black Diamond Therapeutics in a research note issued on Wednesday...

Implied Volatility Surging for Black Diamond Therapeutics Stock Options

Investors need to pay close attention to BDTX stock based on the movements in the options market lately.

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Black Diamond Therapeutics Inc

Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$BDTX - when are the deep pockets planning to get off the bunny slope and onto the black diamond?

Retail_Investor

$BDTX look forward for tuesday. Wainwright 28th Annual Global Investment Conference. If the management will be vague and elusive... that is the sign!

alberto

$BDTX 
The excellent data presented at ASCO on the phase 2 study of silevertinib had a cutoff date of April 11. Another 6 months have now passed for the patients on treatment. It would appear that the data have matured in an astonishing way. Best-in-class and unmet need. Fasten your seatbelts

$BDTX any yet again flat in a massive biotech spike! anyone alive/awake at this company? not even small/midcap funds buying any more?

Daniel Koller

$BDTX patent protection of keytruda and others is running out...big pharma will look for new drugs. And silevertinib is best in class for rare mutations and to block de novo mets. Its a fact...do the math

$BDTX - man, I could really use a lambo this weekend, sunny and dry in the 70s, nice weather for a coastal drive …

$BDTX wrong direction, again... every time yields go up small/mid gets crushed, thats why it is beyond frustrating when BDTX never goes up on up days.. a looooong wait for Mark to get his act together, hopefully

$BDTX 

Not sure why people bitching. 12% above average volume with sideways movement in price. There is a large consolidation window here, you could have bought $1.60 and you could have bought $2.30. Either way, you are golden

Boss

$BDTX great to see blossomhill add the mrktcap of BDTX today... drives me mad to be in this looser

$BDTX 

3 readouts next 15 months, FDA and trial update within next 1-2 months, possible partnership and priority voucher. 

Doesn’t get any better than this

$BDTX 

Unfortunately this is part of arbitrage in today’s market. You sometimes get sleeper deals but surely once news comes out they rip.

Thing is, these low volume plays are also dominated by short algos which help consolidate lower levels for more explosive upsides. Crack open 12 month chart,

More than evident

BDTX Black Diamond Therapeutics Inc